Hyperandrogenism is associated with hyperinsulinemia and insulin resistance in adult females. We tested whether androgens dysregulate pancreatic beta cell function to induce hyperinsulinemia through transcriptional regulation of insulin gene (Ins) in the islets. Adult female Wistar rats implanted with dihydrotestosterone (DHT; 7.5-mg, 90-d release) or placebo pellets were examined after 10 weeks. DHT exposure increased plasma DHT levels by 2-fold similar to that in polycystic ovary syndrome in women. DHT exposure induced hyperinsulinemia with increased HOMA-IR index in fasting state and glucose intolerance and exaggerated insulin responses following glucose tolerance test. DHT females had no change in islet number, size and beta cell proliferation/apoptosis but exhibited significant mitochondrial dysfunction (higher ADP/ATP ratio, decreased mtDNA copy number, increased reactive oxygen production and downregulation of mitochondrial biogenesis) and enhanced glucose-stimulated insulin secretion. Ins expression was increased in DHT islets. In vitro incubation of control islets with DHT dose dependently stimulated Ins transcription. Analysis of Ins1 gene revealed a putative androgen responsive element in the promoter. Chromatinimmunoprecipitation assays showed that androgen receptors bind to this element in response to DHT stimulation. Furthermore, reporter assays showed that the promoter element is highly responsive to androgens. Insulin-stimulated glucose uptake in skeletal muscle was decreased with associated decrease in IRβ expression in DHT females. Our studies identified a novel androgenmediated mechanism for the control of Ins expression via transcriptional regulation providing a molecular mechanism linking elevated androgens and hyperinsulemia. Decreased IRβ expression in the skeletal muscles may contribute, in part, to glucose intolerance in this model. -cell hyperinsulinemia, 2018, Vol. 98, No. 4 
Introduction
Polycystic ovary syndrome (PCOS) is a common heterogeneous endocrine disorder characterized by hyperandrogenism and polycystic ovaries [1] . The prevalence of PCOS varies depending on which criteria are used to make the diagnosis, but is as high as 15%-20% when the American Society for Reproductive Medicine/European Society for Human Reproduction and Embryology criteria is used [1] . PCOS has a tremendous negative impact on the physiology and metabolism of the body as it evolves into a metabolic syndrome with insulin resistance, hyperinsulinemia, abdominal obesity, hypertension and dyslipidemia. Of these metabolic traits, insulin resistance is considered to be the central component of PCOS pathogenesis which leads to other comorbidities that culminate into serious longterm consequences, such as type 2 diabetes mellitus, endometrial hyperplasia and cardiovascular disease [1] . Insulin resistance occurs in ∼70% of PCOS women, of which 50% develop type 2 diabetes before the age of 40 [2] [3] [4] . Impaired insulin action at peripheral target tissues (i.e. peripheral insulin resistance) and defective insulin secretion are proposed mechanisms that contribute to insulin resistance [5] . While peripheral target tissue resistance to insulin has been well documented as a factor that contributes to the reproductive and metabolic phenotypes of PCOS, the role of abnormal insulin secretion has received little attention. The latter is important because recent studies assessing the peripheral insulin sensitivity in PCOS using the "gold standard" method, the hyperinsulinemic euglycemic clamp indicated that peripheral insulin sensitivity is well within the range of that in reproductively normal control women of comparable age [6, 7] , suggesting that decreased peripheral insulin sensitivity may not be a primary risk factor for the development of type 2 diabetes in women with PCOS. Therefore, defects in insulin secretion as well as familial and environmental factors need to be considered to obtain a better understanding of why women with PCOS are predisposed to type 2 diabetes.
Dysfunction of pancreatic beta cells-which are responsible for the secretion of insulin-is a characteristic of both type 1 and type 2 diabetes [8, 9] . Of the limited number of studies that have investigated pancreatic beta cell function in PCOS, some have described increased insulin secretion [10] [11] [12] , while others suggest decreased insulin secretion [13] [14] [15] . For example, beta cell dysfunction is suggested to be a key pathogenic determinant in PCOS [16] . Women with hyperandrogenic PCOS were shown to have higher basal insulin secretion rates [17] and this was ascribed to beta cell dysfunction independent of insulin resistance [10, 14, 18, 19] . Recently, a role for oxidative stress and inflammation induced in mononuclear cells has been confirmed in beta cell dysfunction in PCOS [20] ; however, the underlying mechanisms remain unclear. In particular, the relationship between increased androgens and impaired pancreatic beta cell function in PCOS has not been clearly established.
The aim of the present study was to elucidate potential mechanisms involved in beta cell alterations in a previously described rat model of PCOS that exhibits metabolic as well as reproductive features of PCOS (24) (25) (26) . We used this model to elucidate (1) whether androgen excess plays an underlying role in altering beta cell structure and insulin secretion, (2) investigate the molecular mechanism by which androgens transcriptionally modulate insulin expression and secretion, and (3) determine whether regulation of insulin action in skeletal muscles play a role in mediating glucose intolerance.
Methods

Dihydrotestosterone treatment and animal care
The Institutional Animal Care and Use Committee at University of Wisconsin-Madison and University of Texas Medical Branch at Galveston approved experimental protocol, and procedures are in accordance with the National Institute of Health guidelines (NIH Publication No. 85-23, revised 1996) for care and use of animals. Female Sprague-Dawley rats were used for this study. Rats were purchased from Envigo laboratories at 8 weeks of age and maintained on 12-h day/night cycles in a temperature-controlled room (23
• C) and provided with food and water ad libitum. Rats were randomly divided into control and dihydrotestosterone (DHT) treatment groups (n = 10 in each group). DHT group rats were implanted with DHT pellets (7.5-mg, 90-d release) for 10 weeks, and control rats were implanted with matched placebo pellets. This dose and duration of DHT were selected to mimic 2-fold increases in androgen levels in PCOS females [21] [22] [23] [24] [25] . At the end of the 10 weeks experimental period, rats were subjected to glucose tolerance test and then sacrificed by CO 2 inhalation. Pancreas was collected for islet isolation, histology and DNA, mRNA and protein extraction, plasma/serum was separated for hormone measurements and skeletal muscles were used for glucose uptake and western blotting.
Plasma DHT, glucose, insulin, and C-Peptide measurement DHT were measured using ELISA kit (RCD009R; BioVendor, Asheville, NC) as in our previous publication [26] . The minimum detectable concentration of DHT is 6 pg/mL and the intra-and interassay coefficients of variation for DHT assay was lower than 8%. Blood glucose levels were measured using an automatic glucometer (StatStrip; Ref 42214; Nova Biomedical, Waltham, MA). Insulin was measured using a rat insulin ELISA kit (10-1250-01; Mercodia, Winston Salem, NC) following the manufacturer's instruction. Briefly, heparinized blood was centrifuged for 15 min at 3000 rpm and 4
• C for plasma isolation, and 10 μl of plasma or calibrators and 100 μl of enzyme conjugate were mixed and incubated for 2 h at room temperature with constant shaking. After washing, 200 μl of 3,30,5,50-tetramethylbenzidine (TMB) substrate were added and incubated for 15 min for color development. The reaction was then stopped by adding 50 μl of stop solution. Absorbance was read at 450 nm using a FLUOstar Omega plate reader (BMG Labtech; Cary, NC), and the results were calculated with cubic spline regression fit using FLUOstar Omega data analysis software. The sensitivity of the insulin assay is 0.07 g/L, with an inter-and intraassay precision of 3.3 and 1.8, respectively.
C-peptide in the plasma was measured using a solid-phase twosite enzyme immunoassay (10-1172-01; Mercodia). Ten microliters of plasma or calibrators and 50 μl of assay buffer were mixed and incubated for 1 h at room temperature with constant shaking. After washing, 100 μl of enzyme conjugate were added, followed by a 1-h incubation at room temperature with constant shaking. Two hundred microliters of substrate TMB were added after a final wash and incubated for 15 min on the bench. The reaction was then stopped by adding 50 μl of stop solution. Absorbance was read at 450 nm using a FLUOstar Omega plate reader, and the results were calculated with cubic spline regression fit using FLUOstar Omega data analysis software. The sensitivity of the C-peptide assay is 27.5 pmol/L −1 , with an inter and intra-assay precision of 2.9 and 4.4, respectively.
Homeostatic model assessment
Insulin resistance (homeostatic model assessment [HOMA]-IR) and insulin sensitivity (HOMA-IS) were calculated as described by Hsing et al. [27] and Park et al. [28] as follows:
Intraperitoneal glucose tolerance test
Rats were fasted overnight for 14 h and then given glucose (2 g/kg) using intraperitoneal injections. Blood was collected before (time 0) and after 15, 30, 60, 90, and 120 min of glucose administration and used for determination of glucose and insulin levels.
Pancreatic morphology, immunohistochemistry, proliferation, and apoptosis assay
Pancreatic tissue was processed as previously described [29] . In brief, the pancreas was dissected and fixed in 4% formaldehyde before being embedded in paraffin. Then, 5-μm sections were deparaffinized and rehydrated, followed by heat-induced antigen retrieval. Six nonserial pancreatic sections per female rat, separated by at least 200 μm, were stained with hematoxylin and eosin. Sections were also immunostained with insulin (1:300; ab181547; Abcam, Cambridge, MA) and proliferation marker Ki67 (1:300; #9129; Cell Signaling Technology, Danvers, MA). Secondary incubations were performed at room temperature for 1 h using anti-rabbit (Alexa Fluor 488; A-11034; Invitrogen, Eugene, OR) and anti-mouse (Alexa Fluor 594; A-11032; Invitrogen) antibodies at 2 μg/ml concentration. Sections were imaged with Leica TCS SP8 confocal microscope (Buffalo Grove, IL) at 40× magnification. For each animal, an average of 30 islets from four random fields on at least six nonserial sections spanning both proximal and distal areas of the pancreas were evaluated as described by Huang et al. [30] . In each pancreatic section, the number of islets, mean islet area, fluorescent intensity, and beta cell area were measured using ImageJ software (http:/rsh.info.nih.gov/ij/). Islet number was defined as the number of islets per microscopic field. The number of islets and insulin staining (florescent) intensity was expressed per square micrometer of the total area of the pancreas. For islet size, images of islets were traced and analyzed with the use of ImageJ software. Islet size was examined as the total islet area divided by the total number of islets. The islet size was examined by analyzing four clusters per pancreatic section. Beta cell area was digitally quantified based on insulin staining using ImageJ software and presented as percent of total pancreatic area [31] . For apoptosis, TdT-mediated dUTP nick end labeling (TUNEL) assay was done in deparafinnized pancreatic sections using in situ apoptosis detection kit (S7110; Millipore, Billerica, MA) according to manufacturer's instructions. Sections were double labeled with insulin to help identify islets. Negative controls were developed with the same protocol, less the addition of the primary antibodies.
Islet isolation and culture
Islets were isolated and cultured using collagenase digestion method as previously described [32] . Briefly, rat pancreas was perfused with 20 ml 1% solution (wt/vol 20 mg/20 mL) of type XI collagenase (Sigma, St. Louis, MO) diluted in cold hank balanced salt solution (HBSS) into the rat pancreatic duct via catheter. The pancreas was minced with scissors and incubated in a shaker-type water bath at 37
• C for 8-10 min. The pancreatic digest was poured into a blackbacked petri dish, and islets were hand-picked under a microscope.
Freshly isolated islets were transferred to sterile 6-well plates and cultured in RPMI 1640 (Gibco; Thermo Scientific, Grand Island, NY) containing 5.5 mmol/L glucose supplemented with 10% fetal bovine serum (FBS) (Gibco), 100 units/mL penicillin, and 100 μg/mL streptomycin (Gibco). Islets were allowed to equilibrate overnight before further treatment or processing. Islet purity was more than 98% as evaluated by dithizone (diphenyl thiocarbazone) method [33] .
Mitochondrial function in isolated islets
ADP/ATP ratio Intracellular ADP to ATP ratio in islets was quantified using the ApoSENSOR ADP/ATP kit (K225; Biovision, Milpitas, CA) as described previously [34] . Briefly, 100 μl reaction buffer containing ATP monitoring enzyme and nucleotide releasing buffer were used as blank to determine the background luminescence. After that, 100-150 islets were treated with reaction buffer for 5 min and then transferred to luminometer plate to record the ATP luminescence. For ADP measurements, after basal reading, 1 μl of ADP-converting enzyme was added and reading was done after 2 min of incubation. Based on these values, ATP/ADP ratio was calculated. Luminescence was measured using a FLUOstar Omega luminescence reader (BMG Labtech).
Mitochondrial DNA copy number Mitochondrial DNA copy number was quantified using qRT-PCR based method using rat mitochondrial DNA copy number assay kit (MCN2; Detroit R&D, Detroit, MI) as per manufacturer's instructions [35] . Reactions were performed with 10 ng of DNA and mtDNA copy number that were normalized with nuclear DNA copy number using the 2 -CT method.
Intracellular ROS measurement
Intracellular ROS levels were determined using the fluorogenic probe 2 ,7 -dichlorodihydrofluorescein diacetate (H2DCF-DA) (D399; Invitrogen) as previously described [36, 37] with some modifications. Briefly, 100-150 islets were loaded with 10 μM H2DCF-DA for 45 min at 37
• C, 5% CO 2 . After incubation, DCFDA-loaded cells were washed twice with phosphate buffered saline (PBS) and fluorescence emission from 2 ,7 -dichlorofluorescein (DCF) was detected at Downloaded from https://academic.oup.com/biolreprod/article-abstract/98/4/520/4819283 by OUP site access user on 08 October 2018 485 nm excitation and 528 nm emission using FLUOstar Omega fluorometer (BMG Labtech). For normalization, protein concentration was measured using BCA protein assay kit (23225; Pierce; Thermo Scientific). Normalized results were expressed as percent relative fluorescence.
Mitochondrial biogenesis-PGC1α mRNA expression
Peroxisome proliferator-activated receptor γ coactivator 1α (Pgc1α) transcription was determined through quantitative real-time (qRT)-PCR method. Total RNA from islets was extracted using RNeasy mini kit (Qiagen, Valencia, CA) according to manufacturer's instructions. RNA concentration and integrity was determined using DS-11 spectrophotometer (DeNovix, Wilmington, DE). One microgram of total RNA was reverse transcribed using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). After dilution, cDNA corresponding to 100 ng of RNA was amplified by qRT-PCR using FAM (Invitrogen) as the fluorophore in a CFX96 real-time thermal cycler (Bio-Rad). PCR conditions for TaqMan Gene Expression Assay were 2 min at 50
• C and 10 min at 95
• C for 1 cycle, then 15 s at 95
• C and 1 min at 60
• C for 50 cycles. Results were calculated using the 2 -CT method and expressed in fold change of the gene of interest in treated versus control samples. All reactions were performed in duplicate, and β-actin was used as an internal control. TaqMan assays were carried out in 10-μl volumes for real-time PCR at a final concentration of 250 nM TaqMan probe and 900 nM of each primer. PGC-1α (Rn00580241 m1) and β-actin (Rn00667869 m1) assays obtained from Assay-on-Demand (Applied Biosystems; Thermo Scientific).
Glucose-stimulated insulin secretion in islets
Isolated islets were first incubated for 45 min at 37
• C in Krebsbicarbonate buffer (containing 5.6 mmol/l glucose and equilibrated with 95% O 2 -5% CO 2 , pH 7.4). Following incubation, solution was replaced with fresh Krebs-bicarbonate buffer and the islets were incubated for 1 h with medium containing 2.8 and 16.7 mmol/l of glucose. Insulin secretion in the supernatant was measured by ELISA (Mercodia) and values were normalized with total islet protein determined by BCA kit (Pierce).
Islet incubations with DHT
Isolated control islets were allowed to recover overnight in complete RPMI medium. After recovery, islets were treated with vehicle and increasing concentration of DHT for 24 h for insulin RNA expression studies.
Insulin RNA expression in islets mRNA quantification of Ins1 and Ins2 gene was done through qRT-PCR using Ins1 (Rn00560677 s1), Ins2 (Rn00560677 s1), and β-actin (Rn00667869 m1) assays obtained from Assay-on-Demand (Applied Biosystems; Thermo Scientific).
Bioinformatic analysis
Bioinformatic analysis was performed on the rat Ins1 (Gene ID: 24505) and Ins2 (Gene ID: 24506) at the promoter region using ConSite web-based prediction tool [38] for the presence of putative androgen response element (ARE) sequences using 75% transcriptional factor cut off score. The analysis was performed up to 4 kb upstream to the transcriptional start site to cover the promoter region and entire intron 1 region, which is in the 5 untranslated region directly upstream to the initiation codon. The predicted putative ARE sequences present on the positive DNA strands of Ins1 were considered for further analysis by chromatin immunoprecipitation (ChIP) assay.
ChIP assay and qPCR
ChIP assay was performed to screen for androgen receptor (AR)-binding sites in the promoter region of the ins1 gene. The assay was performed using a SimpleChIP ChIP kit (#9005; Cell Signaling Technologies) following the manufacturer's instruction. Briefly, pancreatic tissues from control and DHT-treated female rats were washed and cross linked by incubating them with 1% formaldehyde for 10 min at room temperature. Cross linking was stopped by the addition of 1X glycine for 5 min. After washing with ice-cold PBS, tissues were lysed to prepare chromatin. The chromatin was then fragmented by enzymatic digestion using micrococcal nuclease for 20 min at 37
• C with frequent mixing. The digestion was stopped by adding 0.5 M EDTA on ice. Next, the nuclei were pelleted and sonicated for 20 s twice with 40% power to break the nuclear membrane. The lysates were then clarified by spinning at 10 000 rpm for 10 min at 4
• C. The supernatant contained the required cross linked chromatin. The chromatin was then treated with RNase A and then incubated with Proteinase K for 2 h at 65
• C. DNA from the digested chromatin was isolated using spin columns, quantified, and run on a 1% agarose gel to verify the enzymatic digestion of chromatin. Chromatin (5 μg of DNA in 500 μl volume for each immunoprecipitation) was then subjected to immunoprecipitation with an AR antibody (25 μl per reaction, Abcam; ab74272) along with positive (10 μl anti-histone antibody; Cell Signaling Technologies #4620) and negative (1 μl of rabbit IgG, Cell Signaling Technologies #2727) controls. Immunoprecipitation was performed overnight at 4
• C with constant rotation. ChIP-grade Protein G magnetic beads were then added to each reaction and incubated for 2 h at 4 • C with rotation.
Next, the pellets were precipitated using a magnetic rack. Cross links were then reversed by adding 5 mM NaCl and proteinase K and incubating at 65
• C for 2 h. DNA was purified using spin columns, quantified, and stored for further analysis. Purified DNA from ChIP assays along with their respective 2% inputs were subjected to qPCR to identify the ligand-dependent AR binding to putative AR-binding sites in ins1 gene. Primer sets were synthesized to flank the predicted putative ARE sites (Table S1) 
Plasmids
Rat AR was cloned into pGL3 basic vector as described previously [39] . Rat Ins1 promoter (0.8 kb upstream of the transcription start site) was amplified with PCR using 5 sense primer 5 -TGCG-CATCACCAGAGATTTTTCTCAG -3 and 3 antisense primer 5 -GGGAGTTACTGG GTCTCCACTAGC -3 primer pairs. Genomic DNA of rat pancreas was used as a template. After electrophoresis on an agarose gel, the PCR products were purified using a QIAquick Gel Extraction kit (28704; Qiagen, Valencia, CA). The purified PCR products were then digested overnight at 37
• C with MluI and XhoI (Fermentas, Waltham, MA) and ligated into the pGL3 luciferase reporter vector (Promega, Madison, WI) by T4 DNA Ligase (Fermentas).
Reporter assay
The upstream promoter region (approximately 800 bp) of the rat Ins1 gene was cloned and sequenced (Gene ID: 24505) and a reporter construct was made by inserting it into pGL3 basic vector (Promega). HEK cells were transiently transfected using Fugene HD transfection reagent (Promega). Each transfection was performed using pGL3-pARE1 and pmaxGFP vector DNA with ∼5 × 10 5 HEK cells. Control transfections were also performed with pGL3 and pmaxGFP vectors to check for background and transfection efficiency, respectively. After 24 h, cells were washed and were incubated in the presence of vehicle (ethanol), DHT (10 nM), and DHT + hydroxyflutamide (1 μM) for 24 h in DMEM containing 4.5 g/L glucose, supplemented with 25 mM HEPES, 2 mM Lglutamine, and antibiotics without sodium pyruvate and FBS at 37
• C with 5% CO 2 . The cells were then washed with ice-cold PBS twice and were lysed by adding 250 μl of passive lysis buffer per well (Promega). A luciferase assay was performed using the Luciferase reporter assay system (E1500; Promega), following the manufacturer's instruction. Cell lysates (20 μl) were transferred on to a 96-well plate and GFP fluorescence was measured using FLUOstar Omega (BMG Labtech). After that, 100 μl of luciferase assay reagent was dispensed in the same plate and luminescence was measured using Fluorstar Omega. The luciferase activity was normalized with GFP florescence and results were expressed as relative luminescence.
Glucose uptake by skeletal muscle
Glucose uptake assays in isolated muscles were performed as described previously [40] . Briefly, soleus muscles were incubated in 8 ml of Krebs-Ringer Modified Buffer (KRB) buffer (117 mmol/l NaCl, 2.5 mmol/l CaCl2, 1.2 mmol/l KH2PO4, 1.2 mmol/l MgSO4, and 24.6 mmol/l NaHCO3, pH 7.4) containing 2 mM pyruvate with or without insulin (1 mU/ml) for 50 min at 37
• C. Following incubation, glucose transport was measured in 2 ml KRB buffer containing 1 mM 2-deoxy-D-[1-3 H]-Glucose (1.5 μCi/ml) and 7 mM D-[14C]-mannitol (0.3 μCi/ml) and incubated for an additional 10 min with or without insulin at 30
• C for 30 min. Both incubation and transport buffers were continuously gassed with 95% O 2 -5% CO 2 . Following incubation tissues were washed in KRB buffer and frozen in liquid nitrogen followed by homogenization in 10% trichloroacetic acid (TCA) and particulates were precipitated by centrifugation at 13 000 g for 2 min. 3 H and 14 C radioactivity present in 300 μl of the supernatant was measured by scintillation counting. Blanks were subtracted from values obtained from muscle derived from the same animal that had been through the same treatments in the absence of radioactivity. From the 14 C specific radioactivity, the extracellular water volume present in the muscle was calculated. This enables the extracellular 3 H volume to be determined and subtracted from 
Western blotting of IRβ in skeletal muscle
Gastrocnemius muscle was homogenized in ice-cold radioimmunoprecipitation assay buffer (Cell Signaling Technology) containing a protease inhibitor tablet and phosphatase inhibitor cocktail-2 and -3 (Sigma). Tissue lysates were centrifuged (14 000× g for 10 min at 4
• C), and the protein content was measured using the BCA protein assay kit (Pierce; Thermo Scientific). The supernatant was resuspended in NuPAGE lithium dodecyl sulfate sample buffer and reducing agent (Invitrogen). Proteins (30 μg) alongside Precision Plus Standard (Kaleidoscope; Bio-Rad) were resolved on 4%-12% gradient NuPAGE Bis-Tris gels (Invitrogen) at 100 V for 2 h at room temperature and then transferred onto Immobilon-P membranes (Millipore) at 100 V for 1 h. The membranes were blocked with 5% nonfat dry milk for 1 h and then incubated overnight at 4
• C with IRβ primary antibody. The primary antibodies were rabbit monoclonal IRβ (ab69508; 1:3000 dilutinon; Abcam) and β-actin (# 3700; 1:5000 dilution, Cell Signaling Technology). After washing, the membranes were incubated with secondary antibodies (anti-rabbit or -mouse conjugated with horseradish peroxidase) at 1:10 000 dilutions and detected with the ECL detection kits (Pierce; Thermo Scientific). Densitometric measurement was done using ImageJ software. Results were expressed as ratios of the intensity of a specific band to that of β-actin.
Statistics
Statistical analyses were performed using GraphPad Prism software. Data are presented as the mean ± SEM. Comparisons between the two groups were performed using unpaired Student t-tests. Comparisons between multiple groups were performed using ANOVA, followed by Newman-Keuls tests. Repeated measures of ANOVA were done for experiments performed over time. Differences were considered to be statistically significant at P < 0.05.
Results
DHT exposure leads to hyperandrogenism and hyperinsulinemia in females
Plasma DHT levels were significantly higher (2-fold) in DHT-treated females (230.4 ± 16.2 pg/ml, n = 6, P < 0.05) compared with controls (110.8 ± 11.6 pg/ml, n = 6) ( Figure 1A ). DHT exposure did not alter fasting glucose levels (DHT-6.12 ± 0.61 mmol/L; control-6.46 ± 0.62 mmol/L; n = 6 each) ( Figure 1B ) but significantly increased fasting insulin levels (DHT-146.16 ± 8.7 pmol/L, control-87 ± 10.44 pmol/L; n = 6 each) ( Figure 1C ). To determine whether the increased plasma insulin levels in DHT females were a consequence of increased secretion from β-cells, we also determined C-peptide levels, which are cosecreted with insulin from β-cells at a 1:1 molar ratio, as a reliable measurement of secretion [41] . Fasting C-peptide levels in plasma were higher in DHT females (458.1 ± 45.31 pmol/L; n = 6; P < .05) than controls (281.43 ± 29.57 pmol/L; n = 6) ( Figure 1D ).
An index of insulin resistance, HOMA-IR was significantly increased in the DHT females (6.17 ± 0.96, n = 6, P < 0.05) compared to their controls (3.39 ± 0.35, n = 6) ( Figure 1E ). The HOMA-IS showed the opposite response: insulin sensitivity in the DHT-treated females (4.23 ± 0.52, n = 6) was decreased compared to that in controls (6.78 ± 0.79, n = 6) ( Figure 1F ).
DHT females exhibit glucose intolerance and exaggerated insulin responses
To further characterize the effects of DHT treatment on glucose handling, intraperitoneal glucose tolerance test was performed using 2 mg/kg glucose. After glucose administration, plasma glucose levels were significantly higher in DHT females compared to controls at all time points; 15 min (36.82 ± 1.26 vs. 22.56 ± 2.45 mmol/L, P < 0.05), 30 min (39.52 ± 1.35 vs. 27.57 ± 2.54 mmol/L, P < 0.05), 60 min (32.25 ± 1.93 vs. 15.05 ± 2.47 mmol/L, P < 0.05), and 120 min (20.87 ± 2.30 vs. 7.64 ± 0.84 mmol/L, P < 0.05); n = 6 in each group (Figure 2A, top panel) . Area under the curve (AUC) analysis (mmol/L × 120 min) of glucose responses ( Figure 2A , bottom panel) revealed significant glucose intolerance in DHT females (3564.0 ± 197.0, n = 6, P < 0.05) compared with controls (1914.0 ± 199.9, n = 6). In response to an intraperitoneal glucose challenge, DHT females exhibited significant increase in plasma insulin levels compared to controls at 15 min (155.06 ± 16.99 vs. 93.55 ± 9.05 pmol/L, P < 0.05), 30 min (150.29 ± 14.39 vs. 73.04 ± 15.03 pmol/L, P < 0.05), and 60 min (111.32 ± 18.37 vs. 64.04 ± 9.64 pmol/L, P < 0.05), followed by no difference at 120 min; n = 6 in each group ( Figure 2B, top panel) .
The overall plasma insulin responses, expressed as insulin AUC after intraperitoneal glucose administration, were greater in DHT females (15 085 ± 1827 pmol/L, n = 6, P < 0.05) compared with controls (9166 ± 1502 pmol/L, n = 6) ( Figure 2B , bottom panel).
No change in pancreatic islet size, number and beta cell area in DHT females
To examine if DHT increase in females affected pancreas, sections of pancreas were analyzed for islet numbers, size, and β-cell area. The number of pancreatic islets were not significantly different in DHT females (4.75 ± 0.75; n = 5; Figure 3A ) compared to controls (5.0 ± 0.57; n = 5). Also, islet size (i.e., mean islet area) was similar in DHT females (434.16 ± 56.45 per mm 2 section; n = 5) and controls (384.13 ± 38.94 per mm 2 section; n = 5) ( Figure 3A ), but the intensity of insulin staining in DHT females was greater compared to controls (DHT: 551.64 ± 43.74 vs. control: 386.54 ± 24.51; n = 5) ( Figure 3B ). Percent β-cell area was unaltered between groups (DHT: 26.39 ± 1.58 vs. control: 25.91 ± 0.69; n = 4)
None of the groups exhibited positive TUNEL staining, and DHT treatment did not change the number of Ki67-positive cells compared to controls (data not shown).
Islets from DHT females exhibit significant mitochondrial dysfunction
Next, we evaluated the effect of DHT treatment on mitochondrial function in isolated islets. The ATP content of DHT-treated islets were significantly decreased in parallel with increased ADP content resulting in higher ADP/ATP ratio in DHT-treated islets compared to control (DHT: 9.41 ± 0.99 vs. control: 2.20 ± 0.13; n = 5; P < 0.05; Figure 4A ). Consistent with decreased ATP content measured in islets of DHT females, mtDNA copy number was significantly decreased by approximately 40% in islets from DHT females ( Figure 4B ; n = 5, P < 0.05). Additionally, we also measured ROS production to evaluate oxidative stress in the islets. DHT treatment increased ROS production by 33% compared to controls ( Figure 4C ; n = 5, P < 0.05).
We further evaluated the mRNA expression of peroxisome proliferator-activated receptor γ coactivator 1α (Pgc1α), the master regulator of mitochondrial biogenesis [42, 43] , which was significantly downregulated in islets of DHT-treated rats ( Figure 4D ). Taken together, these data indicate significant mitochondrial dysfunction in islets of DHT-treated rats when compared with controls.
Glucose-stimulated insulin secretion and Ins1 and Ins2 expressions are increased in the islets of DHT females
To determine whether the altered insulin secretion of DHT females was an islet cell autonomous effect, we studied glucose-stimulated insulin secretion in static incubation in cultured islets. Compared with control islets, DHT islets exhibited increased glucose-stimulated insulin secretion at both 2.8 and 16.7 mM glucose ( Figure 5A ; n = 5, P < 0.05). In rats, insulin gene is composed of a two-gene system, Ins1 and Ins2 [42] . In the present study, mRNA levels of both Ins1 and Ins2 were significantly increased in the islets of DHT females compared to controls ( Figure 5B ; n = 5, P < 0.05).
DHT increases Ins gene expression levels in cultured islets
Based on the effects of hyperandrogenism on Ins expression, we next assessed the mechanism of DHT stimulation of Ins expression. We determined the effects of DHT on Ins mRNA levels in an in vitro cell culture model (islets isolated from control animals). Ins1 and Ins2 mRNA levels in cultured islets were dose dependently increased by DHT treatment ( Figure 6A and B, P < 0.05, n = 5), indicating DHT-mediated induction of Ins gene transcription.
AR-binding sites in Ins gene promoter
We probed Ins1 and Ins2 for promoter analysis. Bioinformatics analysis of both promoter regions showed seven putative ARE sequences. Putative AREs identified in the promoter region of Ins1 were named ARE1 to ARE7 ( Figure 7A ). Putative AREs on Ins2 promoter are shown in Supplementary Figure 1 . Since Ins1 is shown to have higher expression and biological activity [43] [44] [45] , we further probed Ins1 with ChIP assay to identify if any of these putative AREs interact with AR in the presence of DHT. Our results show that only ARE1 interacted with AR in a ligand-dependent fashion showing 2-fold enrichment when treated with DHT compared with control treatment ( Figure 7B ; P < 0.05; n = 4). Other predicted putative AREs did not show any ligand-dependent enrichment (data not shown). Thus, our data suggest the presence of a functional ARE sites in the promoter regions of the Ins1 gene.
ARE1 has functional effect in enhancing Ins gene expression
We further probed ARE1 because it showed higher fold enrichment. We cloned and sequenced 800 bp (-976 to -176) promoter region of InsI (Gene ID: 24505) and performed a reporter assay. Results show that AR was able to induce transcription in a liganddependent manner. DHT increased luciferase activity by ∼3-fold and was significantly higher than vehicle (Figure 8 ; P < 0.05; n = 3). Flutamide treatment abolished DHT-mediated luciferase activity (Figure 8 ; P < 0.05; n = 3). Thus, our data suggest that the functional AR binding site in the -800 promoter region of the Ins1 gene has a promoter element like function.
DHT females exhibited lower IRβ protein expression and reduced insulin-stimulated glucose uptake in skeletal muscles
To determine whether the glucose dysregulation in DHT females is due to altered ability of the cells to interact with insulin, expression Representative islets from both groups are shown with original magnification ×40 (A). The number of islets and mean islet area were determined as described in Materials and Methods. Insulin staining intensity-red fluorescence (B) in control and DHT islets were determined using four clusters per pancreatic section and three pancreatic sections per animal. Values are presented as the mean ± SEM of n = 5 animals in each group; * P < 0.05 vs. control. of the β subunit of IR in gastrocnemius muscle was examined. IRβ protein expression in DHT females was significantly lower compared to controls (n = 4; P < 0.05; Figure 9A ). This is consistent with the functional decrease (∼40%) in insulin-stimulated glucose uptake in soleus muscle of DHT females compared with controls ( Figure 9B ; P < 0.05; n = 4).
Discussion
The major findings of this study are that elevated DHT levels, at clinically relevant concentrations, lead to hyperinsulinemia without alteration in pancreatic islet number, size, and β-cell area in adult females. The hyperinsulinemia in DHT females occur in spite of significant mitochondrial dysfunction in the pancreatic islets. We identified a novel androgen-mediated mechanism that controls the expression of Ins in pancreatic islets by positively regulating Ins transcription through a functional ARE in the Ins gene promoter. Therefore, we suggest that increases in islet's androgen-stimulated responses may mediate the development and maintenance of hyperinsulinemia in adult females. The decrease in IRβ protein expression in the skeletal muscle may be a compensatory effect to maintain basal euglycemia in the face of hyperinsulinemia. There is mounting evidence that elevated androgen levels in female rats induce adverse reproductive and metabolic phenotype with similar features to PCOS [44, 45] . In our study, DHT, a nonaromatizable androgen, was selected to avoid the confounding effects of estrogen. The model was designed to create a physiological state of hyperandrogenism that mimics androgen levels observed in women with PCOS. DHT treatment increased plasma DHT levels by 2-fold compared to controls, which is consistent with the available data that DHT levels remain relatively stable across the menstrual cycle and are approximately 2-fold higher in women with PCOS compared with those without PCOS (140-160 pg/mL vs. 70-80 pg/mL, respectively) [46, 47] . Although glucose levels were maintained in the DHT females, they had an increased fasting circulating insulin levels. Surprisingly, the unaltered number and size of islets and β-cell area in DHT females does not substantiate the observed hyperinsulinemia in these animals. Evidence indicates that androgens have paradoxical ability to induce apoptosis [48] , inhibit proliferation [49] and expand islets [50] . Murine studies have demonstrated severely limited beta cell proliferation with advancing age [51, 52] . The lack of increased proliferation of β cells in hyperinsulinemic DHT females illustrates this as well; the adaptation to produce more insulin appears to come from hypersecretive islets rather than an increased number or area of islets. The almost complete absence of apoptosis in these same pancreata, however, attests to the resilience and long life span of beta cells that has also been previously reported [53] . Analysis of C-peptide levels confirms that DHT females are indeed hyperinsulinemic and clarifies that the increase in insulin levels may not be due to deficits in clearance but may be related to increased synthesis. The finding that isolated islets from DHT females exhibit increased glucose-stimulated insulin secretion indicate an autonomous and inherent ability of islets from DHT females to produce higher insulin levels. Consistently, the increased intensity of insulin staining and increased expression of Ins1 and Ins2 genes in the islets of DHT females suggest that DHT females have the ability to produce higher insulin content per β-cell area. This fasting hyperinsulinemia paralleled with euglycemia and increased HOMA-IR suggest insulin resistance.
Upon glucose administration, unlike controls, DHT females exhibited glucose intolerance with elevated plasma glucose (higher glycemia AUC) in spite of having higher insulin levels (higher insulin AUC). The higher insulin levels in DHT females following glucose challenge appears due to elevated baseline concentrations rather than increased responsiveness to glucose. This indicates the inability of DHT islets to mount increased insulin secretion relative to glucose concentrations. Thus, although the fasting glucose levels are unaltered with DHT exposure, the induced effects are severely compromised with inadequate insulin secretory response, which may be a major contributor for the glucose intolerance.
The mitochondria of pancreatic beta cells play a central role in coupling glucose metabolism with insulin secretion, as well as incorporating other sources of energy such as fatty acids and amino acids to amplify glucose metabolism. Mitochondrial loss or functional defects can impair this metabolic coupling [54] . In the present study, DHT treatment significantly decreased both the ATP content and mtDNA copy numbers of the islets suggesting a mitochondrialrelated defect. A previous report also indicated that mtDNA copy numbers in peripheral blood were significantly lower in women with PCOS than in healthy women; this indicates that mtDNA depletion may be involved in the pathogenesis of PCOS and may be a potential link between PCOS and metabolic and hormonal complications [55] . Additionally, reduced expression of regulatory coactivator of mitochondrial biogenesis also supports this scenario [56, 57] . The mitochondrial dysfunction and decrease in mitochondrial copy number may contribute for the inability of the DHT Downloaded from https://academic.oup.com/biolreprod/article-abstract/98/4/520/4819283 by OUP site access user on 08 October 2018 islets to mount compensatory insulin response following glucose challenge. The finding that DHT exposure to cultured islets upregulates Ins1 and Ins2 mRNA suggests insulin is a physiological target for DHT and that androgens can directly regulate the transcription of insulin. Our in silico analysis of a 4-kb region upstream of the Ins1 transcription start site revealed seven tandem ARE-like sequences resembling the ARE consensus sequence. It is known that steroid receptor binding sites can deviate considerably from the consensus high-affinity motif and steroid receptor recognition by low-affinity sites can be significantly enhanced by flanking sequences and coregulators [58, 59] . Importantly, our ChIP studies showed that the ARE1 efficiently binds to AR in response to DHT suggesting its functional relevance in vivo. The luciferase reporter assay of ARE1 showed a ligand-dependent activation, indicating that this sequence is responsive to androgens. Bioinformatic analysis also reveals presence of ARE-like sites in Ins2, which need to be examined in future for functional significance.
The question arises as to how DHT females exhibited fasting euglycemia and glucose intolerance (higher glycemia AUC) in spite of basal hyperinsulinemia and higher insulin levels following glucose challenge (higher insulin AUC). IRβ in the skeletal muscle is the major glucose utilizer and is known to play an important role in maintaining plasma glucose levels [60] . Thus, the reduced IRβ protein levels observed in DHT females may contribute to euglycemia in the face of hyperinsulinemia. Further studies are needed to confirm whether the IRβ decrease in DHT females is secondary to hyperinsulinemia or if androgens directly downregulate IRβ expression and function. Nevertheless, decreased IRβ expression in the face of hyperinsulinemia may be a tradeoff mechanism for maintaining basal normoglycemia. However, the decreased skeletal muscle IRβ expression together with insulin secretory defect of islets may play a role for glucose intolerance when there is a glucose challenge.
In conclusion, our studies identified a novel androgen-mediated mechanism for the control of Ins1 expression via transcriptional regulation that might contribute for basal hyperinsulinemia and euglycemia. The responsiveness of the DHT-exposed islets appears to be lost when there is a glucose challenge, likely due to mitochondrial dysfunction of islets and the associated insulin secretory defect, which together with the reduced skeletal muscle IRβ expression may lead to glucose intolerance. 
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